Press Releases

November 12, 2020
Surrozen to Present at the Stifel 2020 Virtual Healthcare Conference
October 30, 2020
Surrozen Appoints Charles Williams as Chief Financial Officer
October 15, 2020
Surrozen Awarded NIH Grant to Support Development of SZN-043, a Liver-Specific Regenerative Antibody, for the Treatment of Severe Alcoholic Hepatitis
September 25, 2020
Surrozen Expands Board of Directors with Appointment of David J. Woodhouse, Ph.D.
September 16, 2020
Surrozen to Present at Morgan Stanley 18th Annual Global Healthcare Conference
Craig Parker, CEO of Surrozen, to present Surrozen’s advancements in regenerative medicine
August 19, 2020
Surrozen Announces Publication of Second Antibody Platform Technology in Scientific Reports
Novel approach to creating R-spondin-mimetics establishes proof-of-concept for targeted regenerative antibodies
June 19, 2020
Surrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical Trials
IND Candidates Nominated for the Treatment of Liver Disease and Inflammatory Bowel Disease
May 29, 2020
Surrozen and Lonza Announce Partnership for the Development and Manufacture of Surrozen’s Novel Wnt Activating Antibodies
Surrozen is developing first-in-class bi-specific antibodies that selectively stimulate tissue regeneration
Lonza to provide cell line development, drug substance and drug product process development and cGMP manufacturing, and regulatory support for IND filing
Lonza’s Light Path™ cell line development program will be tailored enabling Surrozen to prepare for their IND filing
May 4, 2020
Surrozen Announces Publication of Two Abstracts Providing Evidence for Liver-Targeted Tissue Regeneration
Abstracts originally accepted for 2020 Digestive Disease Week Conference – to be published online
April 6, 2020
Surrozen Scientific Founder Roel Nusse, PhD Receives Prestigious Canada Gairdner International Award for Biomedical Research
Award recognizes Dr. Nusse’s seminal contributions to elucidating the mechanism and role of Wnt signaling
March 20, 2020
Surrozen Announces Publication of Antibody Platform Technology in Cell Chemical Biology
Novel approach to creating Wnt-mimetics establishes proof-of-concept for targeted regenerative antibodies
March 2, 2020
Surrozen to Present at Cowen and Company 40th Annual Health Care Conference
April 11, 2019
Surrozen Appoints Dr. Trudy Vanhove as Chief Medical Officer
March 14, 2019
Surrozen Raises $50 Million in Series B Financing to Advance Regenerative Antibody Platforms and Liver Disease Candidates
Anna Berkenblit, MD, appointed to Surrozen Board of Directors
April 4, 2018
Surrozen Strengthens Leadership Team with Addition of New CEO and Scientific Co-founder
February 15, 2017
Surrozen Launches Into Regenerative Medicine With $33 Million in Series A Financing Led by The Column Group
Founded on key discoveries from Stanford University that enable selective Wnt pathway activation, Surrozen advances novel regenerative medicines with broad applications for human health